Recipharm Enters into Collaboration with Vetcare
News Nov 19, 2012
Recipharm and Vetcare have announced the signing of an agreement for the development and manufacture of a parenteral veterinary product.
Specifically, the product concerned will be developed by Recipharm’s development site in Solna, Sweden and the commercial manufacturing is intended to take place at the company’s site in Monts, France.
Maria Lundberg, General Manager, Recipharm Pharmaceutical Development, commented: “We are pleased to have entered into this collaboration with Vetcare. This project is perfectly suited to Recipharm as it allows us to demonstrate our expertise in formulation and analytical method development with a challenging formulation before performing technology transfer to commercial manufacturing”.
“Michel Saudemon, General Manager of Recipharm in Monts added “this project is excellent news and is a perfect fit for our new smaller scale flexible manufacturing facility which will come on line next year”.
Kalevi Heinonen, Managing Director of Vetcare Oy, commented: “We view this as a highly important industry collaboration that will allow us to launch a novel product with the potential for significant improvement in animal health in the most efficient way. It was vital to us that we partnered with a company that could offer us both development and commercial manufacturing. Also the geographical locations, Sweden and France, are very suitable for us.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE